Actively Recruiting
Comparing Standard Chemotherapy Versus New Drug Combinations Including Venetoclax for High-Risk Acute Myeloid Leukemia in Adults 18 to 59
Led by National Cancer Institute (NCI) · Updated on 2026-11-04
335
Participants Needed
227
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating various treatment regimens for patients aged 18 to 59 with high-risk acute myeloid leukemia AML, a form of blood cancer that is harder to treat. This Phase II trial compares the standard chemotherapy combination of cytarabine and daunorubicin against newer experimental therapies including daunorubicin and cytarabine liposome alone, combinations with venetoclax, and azacitidine with venetoclax. The study aims to assess which regimen can better eliminate measurable residual disease and improve remission rates. Participants are randomly assigned to one of five treatment groups. Treatments involve cycles of chemotherapy drugs administered intravenously or subcutaneously, combined with oral venetoclax in some arms. Each cycle lasts 28 days, with the possibility of additional cycles if there is no disease progression or unacceptable toxicity. Before starting treatment, participants undergo heart function tests ECHO or MUGA scans. Blood and bone marrow samples are collected throughout the trial to monitor disease status and response to therapy. During the study, participants receive scheduled treatments and regular assessments including bone marrow aspirations and blood draws. After completing treatment, follow-up visits occur monthly during the first year, every two months in the second year, every three months in the third year, and every six months up to five years. Researchers will measure outcomes such as remission rates, survival, relapse, and treatment side effects. Specimens are also collected for future research to better understand AML and treatment effects.
CONDITIONS
Brief Title
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here